Market Place
Sourcing Support
Aptorum FY 2023 Results and Business Update
30 Apr 2024 //
BUSINESSWIRE
Aptorum Announces Entering into an Agreement and Plan of Merger with YOOV
06 Mar 2024 //
PRESS RELEASE
Aptorum Group Limited Reports Financial Results
22 Dec 2023 //
BUSINESSWIRE
Aptorum Announces Results of 2023 Annual General Meeting of Shareholders
21 Dec 2023 //
BUSINESSWIRE
Aptorumto Hold Annual General Meeting of Shareholders on December 20, 2023
16 Nov 2023 //
BUSINESSWIRE
Aptorum Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets
10 Aug 2023 //
BUSINESSWIRE
Aptorum Group Receives Nasdaq of Minimum Stockholders’ Equity Deficiency
05 May 2023 //
BUSINESSWIRE
Aptorum Therapeutics Enters Into Letter of Intent and Term Sheet
01 May 2023 //
BUSINESSWIRE
Aptorum Group Limited Reports 2022 Fiscal Year End Financial Results
28 Apr 2023 //
BUSINESSWIRE
Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group
27 Mar 2023 //
BUSINESSWIRE
Aptorum Announces Completion of Pre-IND Discussions with US FDA on its ALS-4
03 Mar 2023 //
BUSINESSWIRE
Aptorum Launches NativusWell, a Novel Nutraceutical for Menopause, in China
02 Mar 2023 //
BUSINESSWIRE
Aptorum Group Regains Compliance with Nasdaq Minimum Bid Price
10 Feb 2023 //
BUSINESSWIRE
Aptorum to Hold Special Extraordinary Meeting of Shareholders on February 21
06 Feb 2023 //
BUSINESSWIRE
Aptorum Group Announces 1-for-10 Reverse Stock Split
20 Jan 2023 //
BUSINESSWIRE
Aptorum Group Announces Results of 2022 Annual General Meeting
22 Dec 2022 //
BUSINESSWIRE
Aptorum Group Announces Completion of $3 Million Convertible Note due 2023
16 Dec 2022 //
BUSINESSWIRE
Aptorum Group Announces Offering of $3 Million Convertible Note due 2023
09 Dec 2022 //
BUSINESSWIRE
Aptorum Publishes Paper on Development of a Sensitive Liquid Chromatography
25 Nov 2022 //
BUSINESSWIRE
Aptorum Group Received Nasdaq Notification Letter Regarding Bid Price Deficiency
18 Nov 2022 //
BUSINESSWIRE
Aptorum Group Limited to Hold Annual General Meeting of Shareholders
08 Nov 2022 //
BUSINESSWIRE
Aptorum Group Limited Reports Financial Results
30 Sep 2022 //
BUSINESSWIRE
Aptorum Group Updates on the Clinical Validation of RPIDD
15 Sep 2022 //
BUSINESSWIRE
Aptorum Group Launches NativusWell, a Novel Nutraceutical for Menopause
15 Sep 2022 //
BUSINESSWIRE
Aptorum to Present at the H.C. Wainwright Annual Global Investment Conference
25 Aug 2022 //
BUSINESSWIRE
Aptorum Group Limited to Present at the H.C. Wainwright Conference
17 May 2022 //
BUSINESSWIRE
Aptorum Group Updates on Data from Completed Phase 1 Clinical Trial of SACT-1
02 May 2022 //
BUSINESSWIRE
Aptorum Group Limited Reports 2021 Fiscal Year End Financial Results
29 Apr 2022 //
BUSINESSWIRE
Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Report®
22 Apr 2022 //
BUSINESSWIRE
Aptorum Group Receives FDA ODD for its SACT-1 Repurposed Drug For Neuroblastoma
20 Jan 2022 //
BUSINESSWIRE
Aptorum Group Granted The First Patent for its SACT-1 Repurposed Drug
18 Jan 2022 //
BUSINESSWIRE
Aptorum Updates on its RPIDD Infectious Disease Liquid Biopsy Technology
10 Jan 2022 //
BUSINESSWIRE
Aptorum Group Launches Oncology & Autoimmune Discovery and Development Platform
10 Jan 2022 //
BUSINESSWIRE
FDA clears Aptorum Group`s IND to Initiate Trials for SACT-1 for Neuroblastoma
15 Sep 2021 //
BIOSPACE
Aptorum Announces New Positive Interim Results from ALS-4 Phase 1 Clinical Trial
13 Jul 2021 //
BUSINESSWIRE
Aptorum Announces Further Positive Interim Results of the Phase 1 Clinical Trial
12 Jul 2021 //
BUSINESSWIRE
Aptorum Group Announces Positive Interim Phase I Clinical Trial
24 May 2021 //
BUSINESSWIRE
Aptorum Group Announces Positive Interim Phase I Clinical Trial Progress
24 May 2021 //
BIOSPACE
Aptorum Group Announces Dosing First Human Subject in a Ph1 Trial of ALS-4
30 Mar 2021 //
BUSINESSWIRE
Aptorum Group Receives Clearance from Health Canada Ph 1 Trial for ALS-4,
20 Jan 2021 //
BUSINESSWIRE
Aptorum Group Announces Submission of Clinical Trial Application for ALS-4
21 Dec 2020 //
BUSINESSWIREINDIA
Aptorum Group Announces Closing of $9.0 Million Public Offering
02 Oct 2020 //
BUSINESSWIRE
Aptorum Group raises $9M in public offering
29 Sep 2020 //
SEEKING ALPHA
Aptorum Group Launches Infectious Disease Liquid Biopsy Subsidiary Start-up
29 Sep 2020 //
BUSINESSWIRE
Aptorum Group Limited Reports Financial Results and Business Update
01 Sep 2020 //
BUSINESSWIRE
Aptorum Group Appoints Dr. Herman Weiss as CEO of microbiome-based platform
19 Aug 2020 //
BUSINESSINSIDER
Aptorum Group Appoints Dr. Herman Weiss as CEO of microbiome-based Claves
19 Aug 2020 //
BUSINESSWIRE
Aptorum Group Becomes the First Nasdaq Listed Biopharmaceutical Company Admitted
23 Jul 2020 //
BUSINESSWIRE
Aptorum Group Interview to Air on Bloomberg International on the RedChip
29 May 2020 //
BUSINESSWIRE
Aptorum Group Limited to Present at the Infectious Disease Virtual Conference
29 Apr 2020 //
BUSINESSWIRE
Aptorum Collaborates with Covar To Investigate at Least 3 Drug Candidates
30 Mar 2020 //
BUSINESSWIRE
Aptorum Group Announces Pricing of $10 Million Registered Direct Offering
26 Feb 2020 //
BUSINESSWIRE
